Abstract:BackgroundIt is unclear whether cerebrospinal fluid (CSF) biomarkers play different roles in mild cognitive impairment (MCI) and Alzheimer's disease. We aimed to investigate whether there is a difference in the correlations between CSF tau, P-tau, and Aβ42 in individuals with normal cognitive function, early MCI, late MCI, or Alzheimer's disease. Additionally, we aimed to identify risk factors for the different diagnoses.MethodsIn this cross-sectional study, we included individuals aged 55–90 years from the Alzheimer's Disease Neuroimaging Initiative (ADNI) with normal cognitive function, early MCI, late MCI, or Alzheimer's disease. From the ADNI, we obtained florbetapir (18F) PET data and concentrations of CSF tau, P-tau, and Aβ42. Partial correlation analysis was performed to assess the correlations between the concentrations of CSF tau, P-tau, and Aβ42 after controlling for age. Multinomial logistic regression was conducted to assess the correlations between demographic and clinical variables in each group.FindingsWe included 558 individuals (140 with normal cognitive function, 233 with early MCI, 125 with late MCI, and 60 with Alzheimer's disease). In the group positive for amyloid plaques on amyloid PET (florbetapir standard uptake value ratio [SUVR] >1·11), a weak correlation existed between CSF Aβ42 and tau in participants with normal cognitive function (r=0·411, p=0·008) or Alzheimer's disease (r=0·298, p=0·027). In the group negative for amyloid plaques on amyloid PET (florbetapir SUVR ≤1·11), a strong positive association existed between CSF Aβ42 and tau in participants with normal cognitive function (r=0·645, p<0·001), early MCI (r=0·560, p<0·001), or late MCI (r=0·486, p=0·003). Aβ42 was significantly correlated with P-tau in individuals with normal cognitive function (r=0·596, p<0·001), early MCI (r=0·543, p<0·001), or late MCI (r=0·395, p=0·019). After adjusting for age, sex, education level, Mini-Mental State Examination (MMSE) score, CSF tau, and CSF P-tau, CSF Aβ42 was significantly associated with early MCI (adjusted odds ratio 0·99, 95% CI 0·99–1·00, p=0·02) and late MCI (0·99, 0·99–1·00, p=0·007) in individuals who were amyloid-PET negative. Among patients who were amyloid-PET positive, factors independently associated with early MCI, late MCI, and Alzheimer's disease were age and MMSE scores.InterpretationIn individuals negative for amyloid plaques on PET, high concentrations of CSF Aβ42 might protect against early and late MCI, although this association needs to be confirmed in future longitudinal studies. The number of patients with Alzheimer's disease with amyloid negativity was too small to allow for multivariate regression analysis.FundingNational Key Research and Development Program (grant number 2016YFC1306505 ), the National Natural Science Foundation of China (grant numbers 81873778 and 81501097 ), and the Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant ( 20152201 ).

Associations between cerebrospinal fluid biomarkers in individuals with normal cognitive function, mild cognitive impairment, or Alzheimer's disease by amyloid PET status: a cross-sectional survey

Association Between CSF Aβ42 and Amyloid Negativity in Patients with Different Stage Mild Cognitive Impairment.

Correlation Between Cerebrospinal Fluid Core Alzheimer’s Disease Biomarkers and Β-Amyloid PET in Chinese Dementia Population

Changes of plasma Aβ and t-tau along with 18F-florbetapir PET in a cohort of cognitive decline

Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients

Prediction of Cerebral Amyloid Pathology Based on Plasma Amyloid and Tau Related Markers

Magnetic Resonance Imaging-Negative Cerebral Amyloid Angiopathy: Cerebrospinal Fluid Amyloid-β42 over Amyloid Positron Emission Tomography

Elevated Tau PET Signal Depends on Abnormal Amyloid Levels and Correlates with Cognitive Impairment in Elderly Persons without Dementia

Age, vascular disease, and Alzheimer's disease pathologies in amyloid negative elderly adults

Plasma biomarker profiles and the correlation with cognitive function across the clinical spectrum of Alzheimer’s disease

Alzheimer’s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline

Plasma Biomarker Profiles and the Association with Cognitive Function Across the Clinical Spectrum of Alzheimer's Disease

Difference of Cerebrospinal Fluid Biomarkers and Neuropsychiatric Symptoms Profiles among Normal Cognition, Mild Cognitive Impairment, and Dementia Patient

Diagnostic and predictive power of plasma proteins in Alzheimer's disease: a cross-sectional and longitudinal study in China

The study on diagnostic feasibility of CSF Aβ42, T-tau, P-tau181 detection in Alzheimer dementia.

Non-linear Character of Plasma Amyloid Beta Over the Course of Cognitive Decline in Alzheimer’s Continuum

Plasma Core Alzheimer?s Disease Biomarkers Predict Amyloid Deposition Burden by Positron Emission Tomography in Chinese Individuals with Cognitive Decline

Tau Pathology Mediated the Plasma Biomarkers and Cognitive Function in Patients with Mild Cognitive Impairment.

Testing cognitive normal for Alzheimer's disease prediction

Association of APOE ε4/ε4 with fluid biomarkers in patients from the PUMCH dementia cohort

Microglial Activation, Tau Pathology, and Neurodegeneration Biomarkers Predict Longitudinal Cognitive Decline in Alzheimer’s Disease Continuum